Stem Cell Clinic

Climb Bio to Host Virtual Investor Event on October 15, 2024

By Global News Feed

WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb Bio’s management team and an external expert who will provide an update to the investment community on the Company’s strategy and focus on developing therapeutics for immune-mediated diseases.

See the article here:
Climb Bio to Host Virtual Investor Event on October 15, 2024

Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors

By Global News Feed

MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya’s board. Mr. Mendel has served as a member of Akoya’s board of directors since June 2021 and has over 30 years of financial and operational management experience.

See the original post:
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2024 it awarded inducement grants to nine new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.

More:
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Helio Genomics Methylation Model Score for Early Cancer Detection Awarded as a Top Abstract for the 2024 San Antonio Liver Cancer Symposium

By Global News Feed

IRVINE, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, today announced that its abstract entitled “Cell-free DNA methylation biomarkers for evaluating prognosis and treatment response in patients with hepatocellular carcinoma”, was selected as one of the top three abstracts, and as a poster presentation, at the 2024 San Antonio Liver Cancer Symposium, to be held at the Hilton Palacio del Rio in San Antonio, Texas from October 11–12, 2024. This study was conducted in collaboration with Ochsner Health.

Original post:
Helio Genomics Methylation Model Score for Early Cancer Detection Awarded as a Top Abstract for the 2024 San Antonio Liver Cancer Symposium

Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

By Global News Feed

CHASKA, Minn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, prior to market open and will host a webcast at 8:30 a.m. Eastern Time. Members of Lifecore’s senior management team will discuss financial results for the first quarter and review recent corporate developments.

The rest is here:
Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million…

By Global News Feed

CINCINATTI, OH., Oct. 03, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Onconetix, Inc. (Nasdaq: ONCO), please note that in the first paragraph of the release, the name of the financial advisor to Onconetix in the transaction had been corrected to Tungsten Advisors. The corrected release follows.

The rest is here:
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million...

→←